既往中重度碘对比剂过敏反应患者再次暴露于低渗碘对比剂的结局:多中心回顾性队列研究
该多中心回顾性队列纳入11个中心150例曾发生中重度低渗碘对比剂过敏反应的患者,共328次再暴露,过敏反应复发率为19.5%。初始反应严重者重度复发率更高,糖尿病、慢性荨麻疹、非碘对比剂药物过敏及初始重度反应为独立危险因素;更换可疑对比剂使复发风险降低67.1%(OR 0.329,P=0.001),而类固醇预用药未见保护作用。
要点
- 更换可疑碘对比剂可使过敏反应复发风险降低67.1%(OR 0.329,P=0.001)。
- 类固醇预用药对预防复发未见保护作用。
- 糖尿病、慢性荨麻疹、非碘对比剂药物过敏及初始重度反应为复发独立危险因素。
核心结论
- 对既往发生中重度低渗碘对比剂过敏反应的高危患者,应考虑更换可疑碘对比剂以降低复发风险。
研究设计与样本
- 多中心回顾性队列研究,纳入11个中心150例患者共328次再暴露;纳入条件为2014年12月前发生中重度低渗碘对比剂过敏反应,且2014年1月至12月间再次行增强CT检查。
诊断标准与关键数值
- 总体过敏反应复发率为19.5%。
- 更换可疑碘对比剂者复发风险降低67.1%(OR 0.329,P=0.001)。
- 初始重度过敏反应患者的重度过敏反应复发率高于初始中度患者,尽管接受了更密集的预用药。
- 多因素分析中复发独立危险因素为糖尿病、慢性荨麻疹、非碘对比剂药物过敏及初始重度过敏反应。
临床应用与阅片要点
- 作者认为,对既往发生中重度低渗碘对比剂过敏反应的高危患者,应考虑更换可疑碘对比剂以降低复发风险。
- 类固醇预用药对预防复发未见保护作用。
- 合并糖尿病、慢性荨麻疹或非碘对比剂药物过敏者复发风险升高。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVES: To evaluate the outcomes of re-exposure to low-osmolar iodinated contrast medium (LOCM) in patients with a history of moderate-to-severe hypersensitivity reaction (HSR).
METHODS: We retrospectively evaluated a cohort comprising all subjects satisfying the following conditions at 11 centres: (1) experienced a moderate-to-severe HSR to LOCM by December 2014, and (2) underwent contrast-enhanced computed tomography after the initial HSR between January 2014 and December 2014.
RESULTS: A total of 150 patients with 328 instances of re-exposure were included; the recurrence rate of HSR was 19.5%. Patients with severe initial HSR exhibited a higher recurrence rate of severe HSR compared to patients with moderate initial HSR, despite more intensive premedication. In the multivariate analysis, the independent risk factors for recurrence of HSR were diabetes, chronic urticaria, drug allergy other than to iodinated contrast media (ICM) and severe initial HSR. The risk of recurrent HSR was 67.1% lower in cases where the implicated ICM was changed to another one (odds ratio: 0.329; P = 0.001). However, steroid premedication did not show protective effects against recurrent HSR.
CONCLUSION: In high-risk patients who have previously experienced a moderate-to-severe initial HSR to LOCM, we should consider changing the implicated ICM to reduce recurrence risk.
KEY POINTS: • In patients with moderate-to-severe HSR, steroid premedication only shows limited effectiveness. • Changing the implicated ICM can reduce the recurrence of HSR to ICM. • Diabetes, chronic urticaria and drug allergies increase the risk of ICM HSR.
引用
- Park HJ, Park JW, Yang MS, et al. Re-exposure to low osmolar iodinated contrast media in patients with prior moderate-to-severe hypersensitivity reactions: A multicentre retrospective cohort study. Eur Radiol. 2016. PMID: 27975150. doi:10.1007/s00330-016-4682-y
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。